ReviewTherapeutic advances in gastroenterology2022
A review of the therapeutic management of Crohn's disease.
Review in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Placebo-Controlled Trials in the Management of Crohn's Disease: An Umbrella Review of Meta-Analyses.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Safety and efficacy of stem cell therapy for Crohn's disease: an umbrella review of systematic reviews.International journal of surgery (London, England) · 2024Pooled it
- Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease.Journal of clinical pharmacology · 2025Trial
- Factors Affecting the Adherence to Partial Enteral Nutrition Combined with the Crohn's Disease Exclusion Diet in Crohn's Disease Adult Patients.Healthcare (Basel, Switzerland) · 2026Article
- Amelioration of Acute Oxazolone-Induced Colitis via Oral Administration of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.Biomedicines · 2026Article
- Region-specific immune regulation determines differential response to JAK1 inhibition in Crohn's disease ex vivo.Journal of Crohn's & colitis · 2026Article
- Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Crotoxin fromFrontiers in immunology · 2026Article
- Current status of 5-aminosalicylic acid in Crohn's disease treatment: a nationwide survey and analysis of perspectives and practice patterns among inflammatory bowel disease physicians.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Mucosal passive immunization with monoclonal antibodies targeting Candidalysin and Hyr proteins attenuates vaginal candidiasis in mice.Virulence · 2025Article
- Short Chain Fatty Acids Lower Inflammation and Restore Intestinal Integrity and Function Markers inNutrients · 2025Article
- Upadacitinib induction therapy in Crohn' s disease: a retrospective real-world study in biologic-refractory patients.BMC gastroenterology · 2025Article
- Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy.Diabetes/metabolism research and reviews · 2025Review
- Ustekinumab versus vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease.Pharmaceutics · 2025Article
- The challenges of implementing earlier surgery for terminal ileal Crohn's disease-A qualitative study of the clinician's perspective.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2025Article
- Efficacy and safety probiotics as adjuvant treatment for Crohn's disease: a meta-analysis of randomized controlled trials.Current research in food science · 2025Article
- Fecal microbiota is associated with extraintestinal manifestations in inflammatory bowel disease.Annals of medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is a chronic inflammatory, relapsing-remitting, and progressive gastrointestinal disorder with an often-negative impact on the physical, emotional, and psychological well-being. Over the past two decades, the medical compendium for the treatment of Crohn's disease has increased significantly, enabling treatment beyond symptoms. Indeed, early and timely use of effective medical therapy has been reflected by improved outcomes with reduction in surgery and ability to achieve clinical and endoscopic remission, reduce corticosteroid dependance, and prevent long-term complications in more patients. In this review, we discuss the key milestones in the medical management of Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.